- Home
- COEP vs RVPH Comparison
COEP vs RVPH Comparison
Compare COEP & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- RVPH
- Stock Information
- Founded
- COEP 2017
- RVPH 2006
- Country
- COEP United States
- RVPH United States
- Employees
- COEP N/A
- RVPH N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- RVPH Health Care
- Exchange
- COEP Nasdaq
- RVPH Nasdaq
- Market Cap
- COEP 32.0M
- RVPH 32.8M
- IPO Year
- COEP N/A
- RVPH N/A
- Fundamental
- Price
- COEP $8.11
- RVPH $0.38
- Analyst Decision
- COEP
- RVPH Strong Buy
- Analyst Count
- COEP 0
- RVPH 5
- Target Price
- COEP N/A
- RVPH $9.00
- AVG Volume (30 Days)
- COEP 32.6K
- RVPH 2.7M
- Earning Date
- COEP 08-15-2025
- RVPH 08-13-2025
- Dividend Yield
- COEP N/A
- RVPH N/A
- EPS Growth
- COEP N/A
- RVPH N/A
- EPS
- COEP N/A
- RVPH N/A
- Revenue
- COEP $62,874.00
- RVPH N/A
- Revenue This Year
- COEP N/A
- RVPH N/A
- Revenue Next Year
- COEP N/A
- RVPH N/A
- P/E Ratio
- COEP N/A
- RVPH N/A
- Revenue Growth
- COEP N/A
- RVPH N/A
- 52 Week Low
- COEP $2.31
- RVPH $0.30
- 52 Week High
- COEP $13.70
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- COEP 44.21
- RVPH 31.16
- Support Level
- COEP $7.25
- RVPH $0.35
- Resistance Level
- COEP $8.86
- RVPH $0.83
- Average True Range (ATR)
- COEP 0.58
- RVPH 0.06
- MACD
- COEP 0.03
- RVPH -0.02
- Stochastic Oscillator
- COEP 48.50
- RVPH 12.96
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.